Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
MetaVia ( (MTVA) ) has issued an update.
MetaVia Inc., a Nasdaq-listed clinical-stage biotech based in Cambridge, Mass., is developing DA-1726 for obesity and vanoglipel for MASH, aiming to reshape treatment of cardiometabolic diseases with gut hormone-based therapeutics. DA-1726, an oxyntomodulin analogue that activates GLP-1 and glucagon receptors, is administered once weekly and has delivered promising weight loss and metabolic benefits in early-stage clinical testing.
On May 11, 2026, MetaVia announced that late-breaking data on DA-1726 were accepted for a poster presentation at the EASL Congress 2026 in Barcelona, scheduled for May 27, 2026, underscoring rising scientific interest in the asset. The selected poster will detail safety, tolerability, pharmacokinetics and pharmacodynamics from a higher-dose Phase 1 cohort with exploratory noninvasive liver assessments, reinforcing MetaVia’s bid to position DA-1726 as a potentially best-in-class obesity therapy with implications for liver disease.
The most recent analyst rating on (MTVA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on MetaVia stock, see the MTVA Stock Forecast page.
Spark’s Take on MTVA Stock
According to Spark, TipRanks’ AI Analyst, MTVA is a Neutral.
The score is held down primarily by weak financial fundamentals (no revenue, ongoing losses, and continued cash burn with equity erosion) and bearish technicals (below key moving averages with negative MACD). Corporate events provide some support via positive clinical progress and added funding, but valuation remains constrained by losses and the absence of a dividend.
To see Spark’s full report on MTVA stock, click here.
More about MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, with lead programs in obesity and Metabolic Dysfunction-Associated Steatohepatitis (MASH). Its pipeline includes DA-1726, a once-weekly oxyntomodulin analogue acting as a GLP-1/glucagon dual agonist, and vanoglipel, a GPR119 agonist targeting gut peptides to improve liver health and metabolic control.
DA-1726 has shown best-in-class potential for weight loss, glucose control and waist reduction in a Phase 1 multiple ascending dose obesity trial, while vanoglipel has demonstrated beneficial effects on hepatic steatosis, inflammation, fibrosis and glucose metabolism in pre-clinical studies and direct hepatic action in a Phase 2a study.
Average Trading Volume: 186,465
Technical Sentiment Signal: Strong Sell
Current Market Cap: $5.55M
See more data about MTVA stock on TipRanks’ Stock Analysis page.